AMIA Comments on FDA Real-World Performance Monitoring and Equity Assessment of AI-Enabled Medical Devices
AMIA commented on FDA's request for public comment regarding real-world performance evaluation of AI-enabled medical devices. We support lifecycle governance with continuous post-market monitoring to address performance drift across diverse populations and settings. AMIA recommends comprehensive metrics beyond accuracy including clinical outcomes, safety, usability, and equity assessment. We emphasize transparent […]